Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312808 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL16005690 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8928066 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL738953 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19173031 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1632799 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL811117 | 0.98 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL48306 | 0.94 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL16376197 | 0.90 | MEN1 (0.56) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL27184892 | 0.90 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7267970-A | — | — | None | — | — | JP | disclosed |
| CN-115304569-A | Method for protecting alcohol-terminated hydroxyl group by using 4-pyridinium methyl benzenesulfonate as catalyst | 浙江世佳科技股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-2565198-B1 | CYCLOPHOSPHAZENE COMPOUND, LUBRICANT COMPRISING SAME, AND MAGNETIC DISK | MORESCO CORP (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20130190399-A1 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) | MARTEK BIOSCIENCES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190399-A1 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) | MARTEK BIOSCIENCES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190399-A1 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) | MARTEK BIOSCIENCES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2011053892-A1 | SYNTHESIS AND USE OF OMEGA-3 AND OMEGA-6 VERY LONG CHAIN POLYUNSATURATED FATTY ACIDS (VLC-PUFA) | MARTEK BIOSCIENCES CORPORATION (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053892-A1 | SYNTHESIS AND USE OF OMEGA-3 AND OMEGA-6 VERY LONG CHAIN POLYUNSATURATED FATTY ACIDS (VLC-PUFA) | MARTEK BIOSCIENCES CORPORATION (US) | 2011-05-05 | — | — | WO | disclosed |
| EP-0675130-B1 | Process for the preparation of phosphonium salts | SHINETSU CHEMICAL CO (JP) | 1999-12-29 | — | — | EP | disclosed |
| US-5481040-A | REACTING A PHOSPHINE WITH A CHLORIDE IN THE PRESENCE OF AN ALKALI METAL SALT AND A SOLVENT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| JP-H07267970-A | METHOD FOR PRODUCING PHOSPHONIUM SALT | SHIN ETSU CHEM CO LTD | 1995-10-17 | — | — | JP | disclosed |
| EP-0675130-A2 | Process for the preparation of phosphonium salts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190399-A1 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) | ELOVL3, ELOVL6, ELOVL1 | MEN1 3371/4885KMT2A 3307/4885KDM4C 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.